Reason for posting: As a nonstimulant, atomoxetine is a popular new treatment for attention-
deficit hyperactivity disorder (ADHD). However, the US Food and Drug Administration and …

AimTo investigate the association between atomoxetine, a drug used in the treatment of
Attention Deficit Hyperactivity Disorder (ADHD), and suicidal ideation, within a cohort of 2 …

BACKGROUND: Antidepressant effects on increased suicidality in children have raised
public concern in recent years. Approved in 2002 for attention-deficit/hyperactivity disorder …

Objective: This meta-analysis examined suicide-related events in the acute phases of
double-blind, placebo-controlled atomoxetine trials in pediatric and adult patients with …

OBJECTIVE:: The present work examined suicide-related events in acute, double-blind, and
placebo-or active comparator-controlled trials with atomoxetine. METHOD:: Fourteen trials in …

An 11 year old boy developed acute agitation and suicidal ideation after commencing
atomoxetine shortly after it was approved for use in Australia. The clinical features were …

BACKGROUND: Atomoxetine, a selective norepinephrine reuptake inhibitor effective in the
treatment of attention-deficit/hyperactivity disorder (ADHD), is metabolized through the …

Atomoxetine (Strattera®) is a selective norepinephrine (noradrenaline) reuptake inhibitor
that is not classified as a stimulant, and is indicated for use in patients with attention-deficit …

Atomoxetine is a selective norepinephrine reuptake inhibitor that is being developed for the
treatment of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine will be the first …

Atomoxetine is a selective inhibitor of norepinephrine reuptake recently approved for the
treatment of attention-deficit/hyperactivity disorder (ADHD). In 4 double-blind, placebo …